Spots Global Cancer Trial Database for Variance of HRD From Paired Ovarian Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Variance of HRD From Paired Ovarian Cancer
Official Title: Variance of HRD From Primary to Recurrent in High-grade Serous Ovarian Cancer
Study ID: NCT05069818
Interventions
Study Description
Brief Summary: Homologous recombination deficiency (HRD) is an important biomarker of poly (ADP-ribose) polymerase inhibitor (PARPi) in patients with high-grade serous ovarian cancer (HGSOC). The stability of HRD in the recurrent HGSOC and its primary pair remains unknown.
Detailed Description: This study intends to perform HRD testing of ovarian cancer in the recurrent HGSOC and its primary pair, furtherly correlate HRD status and clinical characteristics in the recurited population.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
Xiaoxiang Chen, Nanjing, Jiangsu, China
Contact Details
Name: Xiaoxiang Chen Chen, MD,PhD
Affiliation: Jiangsu Cancer Institute & Hospital
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
